Chiedza Kaitano

Bio:

Dr. Chiedza Kaitano is the Vice President and Global Program Head for Obesity at Regeneron, where she leads development, strategy and execution for a diverse portfolio of next-generation obesity therapeutics. Notably, she recently assumed leadership of the lead program in Regeneron’s obesity franchise, the trevogrumab (anti-myostatin) program. This first-in-class therapy targets muscle preservation, underscoring her commitment to science-driven, patient-centric solutions. 

Chiedza leads the strategic program team through successful late-stage development, global launch and lifecycle management. She is instrumental in driving Regeneron’s integrated portfolio strategy for rapid pipeline progression, partnering closely across the Internal Medicine Clinical Development Unit to advance and execute the portfolio. Chiedza is accountable for operational execution across all phases of development, proactively identifying and mitigating risks and ensuring that regulatory milestones are met. Her cross-functional leadership extends to aligning diverse teams to deliver Regeneron’s mission to redefine obesity and metabolic health.  

With nearly 20 years of global experience spanning clinical development and commercial leadership, Chiedza is recognized for advancing breakthrough assets, including GLP-1 and dual agonist therapies, through late-stage development and global launch. Prior to Regeneron, she served as General Manager and Head of Human Pharma for Boehringer Ingelheim in Belgium and Luxembourg, and as Global Asset Lead for survodutide, a glucagon/GLP-1 dual agonist in Phase 3 for obesity and MASH. Prior, she held pivotal marketing and medical affairs roles at Bayer, launching oncology therapies across U.S. and European markets. 

Chiedza earned her PhD and MS in microbiology from the New York University School of Medicine and undergraduate degrees in pre-medicine and zoology from Ohio Wesleyan University.